Teleflex, Inc. (TFX) CEO Liam Kelly on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/28/22
New Data Reinforce Efficacy of the UroLift® System for the Treatment of Enlarged ProstateGlobeNewsWire • 07/01/22
Teleflex launches new Arrow Pressure Injectable Midline Catheter in Australia and New ZealandGlobeNewsWire • 06/13/22
Teleflex launches new Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa regionGlobeNewsWire • 06/07/22
Teleflex Celebrates June Men's Health Month with Launch of UroLift® Patient Ambassador ProgramGlobeNewsWire • 06/01/22
Teleflex Announces Regulatory Clearance for its UroLift® System in China for the Treatment of Benign Prostatic Hyperplasia (BPH)GlobeNewsWire • 05/19/22
Teleflex Announces Full U.S. Commercial Launch of the UroLift® 2 System and UroLift ATC ® Advanced Tissue Control SystemGlobeNewsWire • 05/13/22
Teleflex Incorporated (TFX) CEO Liam Kelly on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/28/22
Teleflex to Present at the Bank of America Securities 2022 Healthcare ConferenceGlobeNewsWire • 04/26/22
Teleflex (TFX) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 04/21/22
Teleflex Announces the Launch of the UroLift® System in Japan for the Treatment of Benign Prostatic Hyperplasia (BPH)GlobeNewsWire • 04/11/22
Teleflex: Diversified Portfolio Of Medical Devices At A Convenient Stock PriceSeeking Alpha • 03/23/22